Full-Time

Automation Scientist

Confirmed live in the last 24 hours

Cellares

Cellares

201-500 employees

Develops and manufactures cell therapies efficiently

Compensation Overview

$90k - $210k/yr

Mid, Senior

San Bruno, CA, USA

Category
Bioinformatics
Computational Biology
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • Master's or Ph.D. in Bioengineering, Biotechnology, Chemistry, Molecular Biology, or a related field
  • 3+ years of relevant experience
  • Experience with assay method development for high-throughput screening
  • Experience with laboratory analytical instruments and automated systems
  • Experience with laboratory information systems (LIMS) and data analysis tools
  • Familiarity with DoE (Design of Experiments) principles and best practices
  • Strong technical writing skills and experience authoring Standard Operating Procedures (SOPs), documentation, and training materials
  • Familiarity with GMP compliance requirements
  • Familiarity with statistical analysis software tools
  • Creative, self-motivated, eager to take on a wide variety of tasks and grow with the evolving technology
  • Self-awareness, integrity, authenticity, and a growth mindset
Responsibilities
  • Collaborate in the design and development of fully automated QC methods
  • Analyze automation workflows to identify bottlenecks and areas for optimization
  • Troubleshoot and resolve technical issues related to automation systems and instrumentation
  • Develop sample and reagent format and storage management strategies
  • Coordinate DoEs (Design of Experiments) to optimize assay method parameters
  • Coordinate the validation and verification testing of automated methods to ensure precision, accuracy, and reproducibility of results
  • Implement quality control measures to maintain the high-quality generation
  • Implement troubleshooting methodologies to identify and resolve complex assay method issues
Desired Qualifications
  • Creative, self-motivated, eager to take on a wide variety of tasks and grow with the evolving technology
  • Self-awareness, integrity, authenticity, and a growth mindset

Cellares develops and manufactures cell therapies in the biotechnology sector, operating as an Integrated Development and Manufacturing Organization (IDMO) that combines both processes in one facility. Its proprietary "Smart Factory" technology features an automated single-use cartridge system, which increases productivity, reduces costs, and lowers process failure rates compared to traditional methods. Cellares serves clients across preclinical, clinical, and commercial stages and has formed partnerships with major pharmaceutical companies for CAR-T cell therapy manufacturing. The company's goal is to provide efficient and cost-effective manufacturing services for cell therapies.

Company Size

201-500

Company Stage

Series C

Total Funding

$355M

Headquarters

South San Francisco, California

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with Bristol Myers Squibb secures $380M for CAR T cell therapy manufacturing.
  • Ossama Eissa's appointment as COO strengthens global Smart Factory expansion efforts.
  • Sony partnership enhances precision in cell therapy manufacturing with advanced flow cytometry.

What critics are saying

  • Emerging competition from companies like bluebird bio threatens Cellares' market share.
  • Rapid Smart Factory expansion may face logistical challenges in international markets.
  • Over-reliance on Bristol Myers Squibb partnership could be risky if dynamics change.

What makes Cellares unique

  • Cellares' Cell Shuttle offers 10x scalability over manual cell therapy manufacturing processes.
  • The Smart Factory technology integrates development and manufacturing, unlike traditional CDMOs.
  • Cell Q automates QC for up to 6,000 batches, reducing manual labor and costs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

3%

2 year growth

5%
RegMedNet
Apr 3rd, 2025
Cell therapy weekly: regulatory boost for automated cell therapy production platform

bluebird bio announced on 21 February 2025 that it had entered into a definitive agreement to be acquired global investment firms Carlyle (DC, USA) and SK Capital (NY, USA) for US$3.00 per share in cash, plus a contingent value right of $6.84 per share if certain sales targets are met.

ROI-NJ
Nov 13th, 2024
Cellares appoints former Novartis, Lonza and Legend Biopharma exec as COO

Cellares, a Bridgewater-based leader in automated cell therapy manufacturing, on Monday announced it appointed Ossama Eissa, former executive at Novartis, Lonza Biologics, and Legend Biotech, as chief operating officer.

ROI-NJ
Nov 13th, 2024
Cellares Appoints Former Novartis, Lonza And Legend Biopharma Exec As Coo

Cellares, a Bridgewater-based leader in automated cell therapy manufacturing, on Monday announced it appointed Ossama Eissa, former executive at Novartis, Lonza Biologics, and Legend Biotech, as chief operating officer.Eissa’s extensive experience will support the expansion of Cellares’ Smart Factory network in the United States, Europe, Japan and other international markets, addressing the challenges of scalability, cost, and quality that have long hindered patient access. Through these advancements, Cellares will work to ensure that life-saving treatments are accessible for oncology and autoimmune patients globally.This appointment strengthens the Cellares leadership team in a time of rapid global expansion of the company’s IDMO manufacturing services, in response to the growing global demand for cell therapy manufacturing capacity.Eissa brings more than 20 years of experience in pharmaceutical and biotech manufacturing.He formerly served as vice president and general manager at Legend Biotech, where he led the Raritan production site through the global launch of Carvykti, a CAR-T cell therapy.At Lonza Biologics, Eissa managed Global Strategic Projects, contributing significantly to the Cell and Gene Technologies Business Unit by boosting manufacturing efficiency and driving commercial scale-up. He also oversaw U.S. manufacturing operations at Novartis, scaling production and supporting regulatory approval for Kymriah, the first FDA-approved CAR-T cell therapy.“Joining Cellares is an opportunity to address one of the biggest challenges in healthcare today: making cell therapies accessible to all of those who need them,” Eissa said. “The mission aligns closely with my experience in scaling complex manufacturing systems to benefit patients directly. I’ve witnessed the profound impact these treatments have, and I’m committed to ensuring that we reach more patients, especially those facing cancer and autoimmune diseases, with the reliability and speed they deserve.”

BioProcess International
Sep 12th, 2024
Cellares and Sony partner to automate cell therapy manufacturing

Self-acclaimed integrated development and manufacturing organization (IDMO) Cellares has partnered with Sony Corporation, a technology firm focused on the field of flow cytometry, to integrate advanced flow cytometry-based cell analysis and sorting solutions into the Cellares Cell Shuttle platform.

Contract Pharma
Sep 3rd, 2024
Cellares Appoints CFO and General Counsel

Cellares, a leader in cell therapy manufacturing and an Integrated Development and Manufacturing Organization (IDMO), has appointed Justin McAnear as Chief Financial Officer (CFO) and Jonathan Butler as General Counsel and Corporate Secretary (GC).